Oppenheimer initiated coverage on ARS Pharmaceuticals with a new price target
$SPRY
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00